Response of Chronic Myeloid Leukemia's Patient to Different Types of Tyrosine Kinase Inhibitors

Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First

Association of Microrna-153-3p Expression in Response to Treatment with Imatinib in Patients with Chronic Myeloid Leukemia

COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION

Study of PTCH1 Gene as a Prognostic Marker to Predict Imatinib Response in CML Patients: a Single Egyptian Center Experience

Philadelphia Chromosome In Acute Lymphoblastic Leukemia

Serum Levels of Angiopoietin-2 and C-Reactive Protein in Chronic Myeloid Leukaemia Patients: Relation to Different Phases of the Disease

Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy

An Innovative Epigenetic Merge in Treatment of AML Patients Correlates with Better "Molecular and Clinical” Outcomes

Results of treatment of adult Egyptian patients with CML using imatinib mesylate